Alzheimer's Society responds to Merck announcement on Verubecestat study

Today, the global healthcare company Merck has announced that it is stopping the EPOCH study, a phase 2/3 study evaluating Verubecestat in people with mild-to-moderate Alzheimer ’s disease.
Source: Alzheimers Society - Category: Geriatrics Source Type: news